Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Restructuring Costs (2024 - 2025)

Cytosorbents' Restructuring Costs history spans 2 years, with the latest figure at -$20.8 million for Q4 2025.

  • Quarterly results put Restructuring Costs at -$20.8 million for Q4 2025, down 421.32% from a year ago — trailing twelve months through Dec 2025 was $102375.0 (down 99.6% YoY), and the annual figure for FY2025 was $102000.0, down 99.61%.
  • Restructuring Costs for Q4 2025 was -$20.8 million at Cytosorbents, down from $6.9 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $7.1 million in Q2 2025 to a low of -$20.8 million in Q4 2025.